Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer

Previous studies suggest beta-adrenergic receptor (β-AR) antagonists (β-blockers) decrease breast cancer progression, tumor metastasis, and patient mortality; however the mechanism for this is unknown. Immunohistochemical analysis of normal and malignant breast tissue revealed overexpression of β1-A...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Montoya, Alexa, Amaya, Clarissa N., Belmont, Andres, Diab, Nabih, Trevino, Richard, Villanueva, Geri, Rains, Steven, Sanchez, Luis A., Badri, Nabeel, Otoukesh, Salman, Khammanivong, Ali, Liss, Danielle, Baca, Sarah T., Aguilera, Renato J., Dickerson, Erin B., Torabi, Alireza, Dwivedi, Alok K., Abbas, Aamer, Chambers, Karinn, Bryan, Brad A., Nahleh, Zeina
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351644/
https://ncbi.nlm.nih.gov/pubmed/28031536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14119
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items